A G Bleicher1, E Kanal. 1. Department of Radiology, Division of Neuroradiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. bleicherag@upmc.edu
Abstract
BACKGROUND AND PURPOSE: With the approval of gadobenate dimeglumine, higher relaxivity MR contrast agents were introduced into the clinical environment, and multiple in vivo studies compared the efficacy and safety with the previously approved agents. An in vitro study was conducted to demonstrate differences between the various agents to confirm published values and for imaging-sequence optimization. MATERIALS AND METHODS: A contrast phantom was made with serial dilutions of commercially available formulations of 5 US Food and Drug Administration-approved gadolinium-based MR imaging contrast agents in human serum substitute. Dilution factors ranging from 1:8 to 1:4096 were included in the phantom. Spin-echo sequences were performed at 1.5T and 3T with varying TRs and TEs. RESULTS: At physiologic concentrations and by using short TRs and TEs, gadobenate demonstrated the highest signal intensities, confirming greater R1 relaxivity. At higher concentrations and with longer TR and TE values, the greatest signal intensity loss was appreciated for gadobenate, confirming greater R2 relaxivity. CONCLUSION: Using rigorous in vitro methodology and serial dilution techniques, this study confirms the reported higher R1 and R2 relaxivities of gadobenate relative to the other agents at 1.5T and 3T.
BACKGROUND AND PURPOSE: With the approval of gadobenate dimeglumine, higher relaxivity MR contrast agents were introduced into the clinical environment, and multiple in vivo studies compared the efficacy and safety with the previously approved agents. An in vitro study was conducted to demonstrate differences between the various agents to confirm published values and for imaging-sequence optimization. MATERIALS AND METHODS: A contrast phantom was made with serial dilutions of commercially available formulations of 5 US Food and Drug Administration-approved gadolinium-based MR imaging contrast agents in human serum substitute. Dilution factors ranging from 1:8 to 1:4096 were included in the phantom. Spin-echo sequences were performed at 1.5T and 3T with varying TRs and TEs. RESULTS: At physiologic concentrations and by using short TRs and TEs, gadobenate demonstrated the highest signal intensities, confirming greater R1 relaxivity. At higher concentrations and with longer TR and TE values, the greatest signal intensity loss was appreciated for gadobenate, confirming greater R2 relaxivity. CONCLUSION: Using rigorous in vitro methodology and serial dilution techniques, this study confirms the reported higher R1 and R2 relaxivities of gadobenate relative to the other agents at 1.5T and 3T.
Authors: Frederik L Giesel; Hendrik von Tengg-Kobligk; Iain D Wilkinson; Peter Siegler; Claus-W von der Lieth; Martin Frank; Klaus P Lodemann; Marco Essig Journal: Invest Radiol Date: 2006-03 Impact factor: 6.016
Authors: Kenneth R Maravilla; Joseph A Maldjian; Ilona M Schmalfuss; Matthew J Kuhn; Brian C Bowen; Franz J Wippold; Val M Runge; Michael V Knopp; Stephane Kremer; Leo J Wolansky; Nicoletta Anzalone; Marco Essig; Lars Gustafsson Journal: Radiology Date: 2006-06-26 Impact factor: 11.105
Authors: Matthew J Kuhn; Piero Picozzi; Joseph A Maldjian; Ilona M Schmalfuss; Kenneth R Maravilla; Brian C Bowen; Franz J Wippold; Val M Runge; Michael V Knopp; Leo J Wolansky; Lars Gustafsson; Marco Essig; Nicoletta Anzalone Journal: J Neurosurg Date: 2007-04 Impact factor: 5.115
Authors: Cesare Colosimo; Philippe Demaerel; Paolo Tortori-Donati; Catherine Christophe; Mark Van Buchem; Barry Högström; Gianpaolo Pirovano; Ningyan Shen; Miles A Kirchin; Alberto Spinazzi Journal: Pediatr Radiol Date: 2005-01-28
Authors: Frank G Shellock; John R Parker; Gianpaolo Pirovano; Ningyan Shen; Carol Venetianer; Miles A Kirchin; Alberto Spinazzi Journal: J Magn Reson Imaging Date: 2006-12 Impact factor: 4.813
Authors: Peter Marckmann; Lone Skov; Kristian Rossen; James Goya Heaf; Henrik S Thomsen Journal: Nephrol Dial Transplant Date: 2007-05-04 Impact factor: 5.992
Authors: Diego R Martin; Saravanan K Krishnamoorthy; Bobby Kalb; Khalil N Salman; Puneet Sharma; John D Carew; Phillip A Martin; Arlene B Chapman; Gaye L Ray; Christian P Larsen; Thomas C Pearson Journal: J Magn Reson Imaging Date: 2010-02 Impact factor: 4.813
Authors: H A Rowley; G Scialfa; P-y Gao; J A Maldjian; D Hassell; M J Kuhn; F J Wippold; M Gallucci; B C Bowen; I M Schmalfuss; J Ruscalleda; S Bastianello; C Colosimo Journal: AJNR Am J Neuroradiol Date: 2008-07-03 Impact factor: 3.825
Authors: Zoran Rumboldt; Howard A Rowley; Fred Steinberg; Joseph A Maldjian; Jordi Ruscalleda; Lars Gustafsson; Stefano Bastianello Journal: J Magn Reson Imaging Date: 2009-04 Impact factor: 4.813
Authors: Xiaolu Yin; Stephen E Russek; Gary Zabow; Fan Sun; Jeotikanta Mohapatra; Kathryn E Keenan; Michael A Boss; Hao Zeng; J Ping Liu; Alexandrea Viert; Sy-Hwang Liou; John Moreland Journal: Sci Rep Date: 2018-08-08 Impact factor: 4.379